Our accomplished Scientific Advisory Board provides support through our clinical research and aids us in our efforts to bring cellular therapy to the community. With our Board’s expertise and specialized advice, RESTEM can continue to develop and implement world-leading cellular therapies.
Keith March, MD, PhD
Director, Center for Regenerative
Medicine, University of Florida
Robert Sackstein, MD, PhD
SVP for Global Health Affairs, Florida International University
Dr. March obtained his M.D. and Ph.D from Indiana University. He is the Director of the Center for Regenerative Medicine at the University of Florida, and throughout his career he has been dedicated to bringing new medical approaches to patients. His publications include more than 170 manuscripts. His laboratory focuses on vascular biology, with a particular emphasis on the function and translational study of stem cells found in the adipose (fat) tissue, which his laboratory identified as cells with critical roles in blood vessel growth and control of inflammation. Dr. March is recognized as a leading expert in the field of adult stem cell research, particularly that involving adipose-derived stem cells. From 2008-2012, he was Chair of the National Institutes of Health Data and Safety Monitoring Board that oversees cell therapy trials in the areas of heart, lung, and blood diseases. Since 2012, he has been an investigator in the Cardiovascular Cell Therapy Research Network (CCTRN), involving seven lead centers in the USA working together to conduct NIH-sponsored cell therapy clinical trials. He has spearheaded FDA approval to conduct multiple U.S. trials employing one’s own fat-derived stem cells or umbilical cord lining-derived stem cells, including an ongoing trial (SUCCESS) to test these cells in the treatment of COVID-19, and three cell-based therapy trials authorized by FDA in early 2021, addressing critical medical needs in other pediatric and adult patient populations.